Actively Recruiting
Dynamics of the Anti-factor VIII Antibody Signature During Treatment With Emicizumab
Led by Christoph Königs · Updated on 2023-07-10
100
Participants Needed
1
Research Sites
344 weeks
Total Duration
On this page
Sponsors
C
Christoph Königs
Lead Sponsor
R
Roche Pharma AG
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this observational study is to learn about the changes of antibodies and inhibitors against the coagulation factor VIII in patients with severe hemophilia A receiving emicizumab therapy. No additional visits or procedures are planned. Patients in this study will continue to receive their routine care and analysis will be done from left over samples from routine visits.
CONDITIONS
Official Title
Dynamics of the Anti-factor VIII Antibody Signature During Treatment With Emicizumab
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Severe congenital hemophilia A (CHA)
- Treatment with emicizumab irrespective of any other treatment
- Informed consent
You will not qualify if you...
- No therapy with emicizumab
- Immunosuppressive therapy
- HIV-infection with CD4 (cluster of differentiation 4) cells <200/µl
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Hospital Frankfurt, Goethe University
Frankfurt am Main, Hesse, Germany, 60590
Actively Recruiting
Research Team
S
Stephan Schultze-Strasser, Dr.
CONTACT
C
Christoph Koenigs, PD Dr. Dr
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here